Status:
UNKNOWN
Comparative Controlled Study of Analgesic, Antiasthenic and Anti-Anxiety Effects of Xenon in Patients With Parkinson's Disease
Lead Sponsor:
Nobilis Therapeutics Inc.
Conditions:
Parkinson Disease
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
This study evaluates the hypothesis that the gas mixture with xenon will have a positive effect on the symptoms in patients with Parkinson's Disease. The study will test the hypothesis that the gas mi...
Eligibility Criteria
Inclusion
- The patient must be male or female over the age of 18.
- The subject must have idiopathic Parkinson's disease.
- The subject has Stage III by Hoehn and Yahr in the "on" state on a screening visit
- Subjects suffering from anxiety, depression, cognitive dysfunction
- Dopaminergic drugs should be taken in a stable dosage for 28 days prior to registration, and throughout the study
- Patients who have signed an approved consent form and are consistent with both the clinical trial plan and follow-up.
Exclusion
- Patients have atypical parkinsonism (eg, neuroleptics, metoclopramide, flunarizin), metabolic neurodegenerative disorders (eg, Wilson's disease), encephalitis, cerebrovascular disease or degenerative disease (e.g. progressive supranuclear palsy)
- Patients who received deep brain stimulation
- Patients with cancer, HIV, kidney or liver disease.
- Patients taking new antipsychotic, antidepressant, anxiolytic or narcotic drugs for less than 3 months
Key Trial Info
Start Date :
December 15 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2021
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT04097080
Start Date
December 15 2019
End Date
December 1 2021
Last Update
March 3 2021
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Institute of Addictology
Moscow, Russia, 129110
2
MONIKI
Moscow, Russia, 129110